Compare Global X SuperDividend ETF (SDIV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Global X SuperDividend ETF trades at $23.65 (market cap $1.18B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 6.4× Global X SuperDividend ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 49 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SDIV | SYRE | |
|---|---|---|
Market Cap | $1.18B | $7.52B |
Volume | 591,359 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $108.92 |
52-Week Low | $23.16 | $22.18 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.88, down 0.21% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, with a 66% price decline since inception noted by Seeking Alpha on September 11, 2026. Recent institutional buying includes Ameritas Advisory increasing its position by 92.6% in Q2 2026 per SEC filings.
High dividend yield attracts income investors but comes with significant capital depreciation risks. Media coverage highlights sustainability concerns, while technical indicators suggest near-term consolidation. The outlook remains cautious due to persistent underperformance versus benchmarks and high volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
